
**Figure 3.**

Mechanism of action of JQ1: induction of cell-cycle arrest and apoptosis. **A**, flow cytometric analysis of the effect of JQ1 on cell cycle in MDA-MB-231 and HS578T. Cells were cultured in DMEM + 10% FBS + 2 mmol/L L-glutamine and treated with JQ1 at 0.2 and 0.5 $\mu\text{mol/L}$. After 12 and 24 hours of treatment, cells were trypsinized, fixed in ice-cold 70% ethanol for 30 minutes, and incubated in PI/RNAse staining solution in the dark for 1 hour at 4°C. Next, cell-cycle progression was examined on FACSCanto II flow cytometer (BD Biosciences). The percentage of stained cells in each phase was gated using the FACS Diva software and represented with a histogram. **B**, biochemical assessment of cell-cycle proteins. Expression of cell-cycle-related regulators (cyclin D1, cyclin D3, cyclin A, cyclin B, cyclin E, p27, p21, pRbS807/811, pRbS780, Wee1, pcdc2, BUBR1, CDK2, and CDK4) was determined in MDA-MB-231 and HS578T after treatment with JQ1 at 0.5 $\mu\text{mol/L}$ at 12, 24, and 48 hours by Western blot analysis. Cell lysates were prepared using a cold lysis buffer containing freshly prepared 20 mmol/L Tris-HCl (pH 7.0), 140 mmol/L NaCl, 50 mmol/L EDTA, 10% glycerol, 1% Nonidet P-40, and protease and phosphatase inhibitor cocktails. (Continued on the following page.)

**Figure 4.**

In vivo antitumor activity of JQ1 and pharmacodynamic evaluation. **A**, *in vivo* effect on tumor growth and weight after JQ1 administration. For xenograft studies, MDA-MB-231 cells (2×10^6 to 5×10^6 cells in 100 μ L of DMEM with 20% Matrigel) were inoculated into the mammary fat pads of mice. After approximately 2 weeks of injection, when tumors reached a volume of 150 mm³, treatment was initiated. Mice were randomly divided into 2 groups: (i) JQ1 treatment ($n = 5$) and (ii) control group ($n = 5$). Animals were treated daily with JQ1 (50 mg/kg intraperitoneally) for 2 weeks. Tumors diameters were serially measured using the following formula: $V = (L \times W^2)/2$, where $V =$ volume (mm³), $L =$ length (mm), and $W =$ width (mm). The Student test was used to calculate statistical significance. After treatment, tumors from control and treated groups were extracted and weight. *, $P < 0.05$. **B**, body weight of nude mice in control and JQ1-treated groups among the duration of the treatment. **C**, protein expression levels of p27 in triple-negative breast tumors after JQ1 administration. Nude mice xenografted with MDA-MB-231 were treated with JQ1 50 mg/kg intraperitoneally for 24 and 48 hours. MDA-MB-231-treated *in vitro* with JQ1 at 0.5 μ M/L was used as control. Tumor samples were minced, washed with cold PBS, and homogenized in cold lysis buffer (1.5 mL/100 mg of tumor). This homogenate was centrifuged at $10,000 \times g$ for 20 minutes at 4°C, and the supernatants were transferred to new tubes. The protein expression of p27 was analyzed by Western blotting as described before. GAPDH was used as a loading control. **D**, effect of JQ1 on the mRNA expression of LMO4, DEPDC, and FOXM1, in treated compared with nontreated tumors. Nude mice injected with MDA-MB-231 were treated with JQ1 (50 mg/kg intraperitoneally) for 24 and 48 hours, and LMO4, DEPDC, and FOXM1 transcription levels were measured by quantitative RT-PCR as previously described.

transcription factors could be involved in the modulation of other genes.

The *in vitro* evaluation of 2 novel BET inhibitors showed antitumor efficacy that was confirmed later using *in vivo* models. Of note, as JQ1 represents a tool compound, relatively high

concentrations (500 nmol/L) was required for optimal effects. Therefore, a medical useful inhibitor would need to be optimized for further development. In any case, their range of activity was still at the nanomolar range. BET inhibitors acted on the G₁ phase of the cell cycle as was observed by flow cytometry, data that are in

(Continued.) Cell extracts (50 μ g of protein) were separated on 6% to 15% SDS-PAGE and, subsequently, immunoblotted using primary antibodies raised against the already mentioned proteins. GAPDH was used as a loading control. **C**, graphical representation of proapoptotic effect of JQ1 on MDA-MB-231 and HS578T. Cells (300,000 per 100-mm dish) treated with JQ1 at 0.2 and 0.5 μ M/L for 24 and 48 hours were incubated in trypsin-EDTA, washed twice with cold PBS, and then stained with Annexin V-DT-634 and PI solution in the dark for 1 hour. Both early (Annexin V-positive and PI-negative) and late (Annexin V-positive and PI-positive) apoptotic cells were determined using a FACSCanto II flow cytometer and were included in cell death determinations. **D**, JQ1 and chemotherapeutics (vinorelbine, docetaxel, cisplatin, and carboplatin) cooperate to induce apoptosis. MDA-MB-231 and HS578T were exposed to drugs alone and in combination with JQ1, at the indicated doses. Apoptosis was examined after 72 hours of treatment by flow cytometry using Annexin V/PI staining as previously described.

line with previous reports in B-cell lymphomas (27, 28). The biochemical evaluation of their function showed a profound effect on proteins that regulate this phase, like an increase of p21, p27, and cyclin D, with a decrease of regulators more associated with latter phases of the cell-cycle cyclin B or BURB. The results from tumors xenografted in animals demonstrated *in vivo* an increase of p27.

An interesting finding was the synergistic interaction between BET inhibitors and chemotherapies used to treat triple-negative tumors—compounds affecting mitosis and producing DNA damage. Evaluation of cell cycle showed that both type of chemotherapies produced an arrest at G₂-M. The combination of BET inhibitors that mainly stop cells at G1 with agents that both induced an arrest at G₂-M suggests that acting of different phases of the cell cycle could be an attractive therapeutic approach. Indeed, BET inhibitors alone did not induce apoptosis in a relevant manner, but their combination with the mentioned agents led cells to a programmed death.

Finally, evaluation of JQ1 in animal models showed that the drug had the same antitumor effect on xenografted tumors confirming the data observed in cell lines. Administration of JQ1 was able to induce the expression p27. Similarly, a reduction of LM04, DEPDC, and FOXM1 was observed after 24 and 48 hours of treatment.

BET inhibitors are a family of compounds with drug candidates at different stages of drug development, from drugs in preclinical stage to others like OTOX15 that has finished its phase I program with signs of activity and no unexpected toxicities (27). For triple-negative breast tumors, BET inhibitors represent a promising therapeutic option that deserves to be evaluated in clinical studies.

In conclusion, our data demonstrate the antitumor efficacy of this family of compounds paving the way of its future clinical evaluation in this unmet disease.

References

- Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. *Science* 2013;339:1546–58.
- Rubio-Perez C, Tamborero D, Schroeder MP, Antolín AA, Deu-Pons J, Perez-Llamas C, et al. *In silico* prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. *Cancer Cell* 2015; 27:382–96.
- Esteller M. Epigenetics in cancer. *N Engl J Med* 2008;358:1148–59.
- West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. *J Clin Invest* 2014;124:30–9.
- Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol* 2009;10:223–32.
- Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. *Nat Rev Drug Discov* 2014;13:337–56.
- Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou MM. Structure and ligand of a histone acetyltransferase bromodomain. *Nature* 1999;399:491–6.
- Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. *Cell* 2013;153:320–34.
- Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. *Mol Cell* 2014;54:728–36.
- Fu LL, Tian M, Li X, Li JJ, Huang J, Ouyang L, et al. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. *Oncotarget* 2015;6:5501–16.
- Shao Q, Kannan A, Lin Z, Stack BC Jr., Suen JY, Gao L. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth *in vivo*. *Cancer Res* 2014;74:7090–102.
- Loosveld M, Castellano R, Gon S, Goubard A, Crouzet T, Pouyet L, et al. Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL. *Oncotarget* 2014;5:3168–72.
- Venkataraman S, Alimova I, Balakrishnan I, Harris P, Birks DK, Griesinger A, et al. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. *Oncotarget* 2014;5:2355–71.
- Asangani IA, Dommetti VL, Wang X, Malik R, Cieslik M, Yang R, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. *Nature* 2014;510:278–82.
- Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, et al. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? *Oncotarget* 2015;6:12890–908.
- Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. *Clin Cancer Res* 2007;13:4429–34.
- Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. *Lancet Oncol* 2007;8:235–44.
- Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, et al. Triple-negative breast cancer: risk factors to potential targets. *Clin Cancer Res* 2008;14:8010–8.
- Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. *Nature* 2010;468:1067–73.
- Noel JK, Iwata K, Ooike S, Sugahara K, Nakamura H, Daibata M. Development of the BET bromodomain inhibitor OTX015. *Proceedings of the*

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: J. Pérez-Peña, G. Serrano-Heras, J.C. Montero, V. Corrales-Sánchez, A. Ocaña

Development of methodology: J. Pérez-Peña, G. Serrano-Heras, V. Corrales-Sánchez, A. Pandiella, A. Ocaña

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J. Pérez-Peña, G. Serrano-Heras, V. Corrales-Sánchez, A. Pandiella, A. Ocaña

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J. Pérez-Peña, G. Serrano-Heras, V. Corrales-Sánchez, A. Pandiella, A. Ocaña

Writing, review, and/or revision of the manuscript: J. Pérez-Peña, G. Serrano-Heras, V. Corrales-Sánchez, A. Pandiella, A. Ocaña

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): V. Corrales-Sánchez

Study supervision: G. Serrano-Heras, V. Corrales-Sánchez, A. Ocaña

Acknowledgments

I would like to thank Pilar F. and Santiago O. for their support.

Grant Support

The study was supported by Instituto de Salud Carlos III (PI13/01444), ACEPAIN; AMAC, Diputación de Albacete and CRIS Cancer Foundation (to A. Ocaña). Ministry of Economy and Competitiveness of Spain (BFU2012-39151 and RD12/0036/0003 to A. Pandiella), and the AECC (to A. Pandiella). J.C. Montero is a recipient of a Miguel Servet fellowship program. European FEDER program.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 20, 2016; revised May 5, 2016; accepted May 17, 2016; published OnlineFirst June 2, 2016.

- AACR-NCI-EORTC international conference: molecular targets and cancer therapeutics; 2013 Oct 19–23; Boston, MA Philadelphia (PA): AACR [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; 2013. Abstract nr C244
21. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, et al. X chromosomal abnormalities in basal-like human breast cancer. *Cancer Cell* 2006;9:121–32.
 22. Kanehira M, Harada Y, Takata R, Shuin T, Miki T, Fujioka T, et al. Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. *Oncogene* 2007;26:6448–55.
 23. Colak D, Nofal A, Albakheet A, Nirmal M, Jeprel H, Eldali A, et al. Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women. *PLoS ONE* 2013;8:e63204.
 24. Tian Y, Wang N, Lu Z. Repression of Lim only protein 4-activated transcription inhibits proliferation and induces apoptosis of normal mammary epithelial cells and breast cancer cells. *Clin Exp Metastasis* 2010;27:455–63.
 25. Jiang L, Wang P, Chen L, Chen H. Down-regulation of FoxM1 by thioestrepton or small interfering RNA inhibits proliferation, transformation ability and angiogenesis, and induces apoptosis of nasopharyngeal carcinoma cells. *Int J Clin Exp Pathol* 2014; 7:5450–60.
 26. Chen H, Zou Y, Yang H, Wang J, Pan H. Downregulation of FoxM1 inhibits proliferation, invasion and angiogenesis of HeLa cells *in vitro* and *in vivo*. *Int J Oncol* 2014;45:2355–64.
 27. Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, et al. The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in pre-clinical B-cell tumor models and synergizes with targeted drugs. *Clin Cancer Res* 2015;21:1628–38.
 28. Trabucco SE, Gerstein RM, Evens AM, Bradner JE, Shultz LD, Greiner DL, et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. *Clin Cancer Res* 2015;21:113–22.

Molecular Cancer Therapeutics

In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment

Javier Pérez-Peña, Gemma Serrano-Heras, Juan Carlos Montero, et al.

Mol Cancer Ther 2016;15:1823-1833. Published OnlineFirst June 2, 2016.

Updated version Access the most recent version of this article at:
doi:[10.1158/1535-7163.MCT-16-0004](https://doi.org/10.1158/1535-7163.MCT-16-0004)

Supplementary Material Access the most recent supplemental material at:
<http://mct.aacrjournals.org/content/suppl/2016/06/02/1535-7163.MCT-16-0004.DC1>

Cited articles This article cites 27 articles, 6 of which you can access for free at:
<http://mct.aacrjournals.org/content/15/8/1823.full#ref-list-1>

Citing articles This article has been cited by 1 HighWire-hosted articles. Access the articles at:
<http://mct.aacrjournals.org/content/15/8/1823.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://mct.aacrjournals.org/content/15/8/1823>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.